Research Article

Related GMR Articles

04/25/2014
ATP-binding cassette; Clinical outcome; Glutathione S-transferases; Osteosarcoma

We conducted a comprehensive study to investigate the role of genes involved in metabolic and transport pathways in response to chemotherapy and clinical outcome of osteosarcoma patients. Genotyping of seven gene polymorphisms was performed on a 384-well plate format on the Sequenom MassARRAY platform in 162 patients with osteosarcoma. We studied the correlation of the seven gene ... more

J.Z. Li; Z.Q. Tian; S.N. Jiang; T. Feng
02/19/2008
Breast cancer; Chemotherapy; P-glycoprotein; Polymorphism

Primary chemotherapy is a useful strategy for the treatment of locally advanced breast cancer and therefore allows in vivo evaluation of the action of cytotoxic drugs and the possibility of accomplishing conservative breast surgeries, as well as the early treatment of metastasis. Mechanisms of resistance to the drugs include the action of protein associated with the efflux of drugs from ... more

F.F.O. Rodrigues; R.E. Santos; M.B. Melo; M.A.L.G. Silva; A.L. Oliveira; R.L. Rozenowicz; L.B. Ulson; T. Aoki
10/31/2014
Chemotherapy; Excision repair cross-complementation group 1; Non-small cell lung cancer; Single nucleotide polymorphism; Survival time

We conducted a cohort study to investigate the role of 3 single-nucleotide polymorphisms of the excision repair cross-complementation group 1 (ERCC1) gene on the response to chemotherapy and clinical outcomes of non-small cell lung cancer (NSCLC). A total of 163 patients with newly diagnosed and histopathologically confirmed primary NSCLC were examined in our study and were ... more

H. Gao; R.C. Ge; H.Y. Liu; Y. Wang; S. Yan
05/16/2014
Chemotherapy; Gene polymorphism; Lung cancer; Meta-analysis; Platinum; XRCC1

X-ray repair cross complementing group 1(XRCC1) polymorphisms have been implicated in interindividual variability of efficacy of platinum chemotherapy for treating non-small cell lung cancer (NSCLC); however, results of different studies have been inconsistent. We conducted a meta-analysis to investigate the association between polymorphisms in the XRCC1 gene and ... more

L. Li; C. Wan; F.Q. Wen
03/06/2014
Chemotherapy; Gastric cancer; Meta-analysis; Polymorphism; XRCC1

It is still controversial whether X-ray repair cross-complementing group (XRCC1) gene polymorphisms (Arg194Trp and Arg399Gln) are associated with the clinical outcome of platinum-based chemotherapy in gastric cancer patients based on published studies. Meta-analysis was performed to provide a systematic review of the findings. Eligible articles from the PubMed, SinoMed, and CNKI ... more

J. Xu; J. Ma; H.T. Zong; S.Y. Wang; J.W. Zhou
01/14/2014
Chemotherapy; Non-small cell lung cancer; XPD; XRCC1

Individual differences in chemosensitivity and clinical outcome of non-small-cell lung carcinoma (NSCLC) patients can be influenced by host-inherited factors. We investigated the impact of XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, XPD Arg156Arg, XPD Asp312Asn, XPD Asp711Asp, and XPD Lys751Gln gene polymorphisms on ... more

L. Zhang; W. Ma; Y. Li; J. Wu; G.Y. Shi
04/13/2015
Cancer stem cells; Chemotherapy; Medulloblastoma; Multidrug resistance; Side population

Brain cancer stem cells are a subset of tumor cells present in several types of brain tumor that evade treatment regimens and are responsible for tumor recurrence. Recent reports on several tumors have suggested that Hoechst 33342 dye exclusion is a powerful technique for isolating cancer stem cell-like side population (SP) cells. In the present study, we attempted to isolate the SP cells ... more

J. Liu; N. Chi; J.Y. Zhang; W. Zhu; Y.S. Bian; H.G. Chen
07/24/2014
BRCA1; Clinical outcome; Non-small cell lung cancer; RRM1

This study aimed to evaluate the association between RRM1 and BRCA1 expressions and the therapeutic efficacy of platinum-based chemotherapy in non-small cell lung cancer patients in terms of their response and prognosis. In total, 377 patients agreed to participate in our study, and all of them received platinum-based combination chemotherapy between January 2008 and ... more

J.G. Liang; Z.Y. Jin; X.D. Gao; M.R. Te; L.H. Ge; C.L. Wang
05/16/2014
Clinical outcome; Hepatocellular carcinoma; Polymorphism; susceptibility; XPD; XRCC1

We explored the association between 4 XRCC1 (Arg194Trp and Arg399Gln) and XPD (Asp312Asn and Lys751Gln) polymorphisms with the development and prognosis of hepatocellular carcinoma (HCC). A total of 218 cases with HCC and 277 healthy controls were included in the study. Genotyping of the XRCC1 (Arg194Trp and Arg399Gln) and XPD (Asp312Asn and Lys751Gln) polymorphisms was ... more

J.S. Wu; Y.P. Chen; L.C. Wang; Y.J. Yang; C.W. Deng; B.X. Hou; Z.L. He; J.X. Chen
04/19/2005
Fab; Human antibody repertoire; Osteosarcoma; Phage display; Recombinant antibody

Osteosarcoma is the commonest type of primary malignant bone tumor, frequently found in adolescents at sites of rapid bone growth. Despite current management protocols, up to half of the patients succumb to this disease. Moreover, there is no well-characterized molecular marker for diagnosis and prognosis. Since phage display methodology allows the selection of human antibody fragments with ... more

C. Dantas-Barbosa; M.M. Brígido; A.Q. Maranhão

Pages